AP127 Molecular Advances in Genito-Urologic Malignancies: Diagnostic and Theranostic Applications

2:00–4:00 pm
2.0 CME CREDITS

This course will cover:

The plethora of molecular biomarkers that have recently been evaluated for their potential role in predicting disease progression, response to therapy, and survival in urologic-malignancy patients
Immunomarkers in prostate biopsies that can facilitate reaching a diagnosis of carcinoma in a small focus of atypical glands
Promising new markers of potential diagnostic or prognostic value (PCA3, TMPRSS2-ERG fusions, and PTEN loss)
Differentially expressed markers that have been valuable in classifying needle biopsies of renal tumors
Opportunities created by new adjuvant targeted therapy protocols for evaluating prognostic/theranostic markers in RCC, including HIF-1a and mTOR pathway members
Molecular markers on the horizon for urothelial carcinoma of bladder that could improve prediction and outcome

You will learn to:

Recognize the translational research-based applications at the interface of genito-urologic pathology and molecular diagnostics
Identify upcoming novel prognostic markers in urologic malignancies

Faculty
George J. Netto, MD, FCAP